{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"44"}],"units":"Participants"}],"description":"The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.","groups":[{"description":"Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma (NHL)"},{"description":"Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Multiple Myeloma (MM)"},{"id":"OG002","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"Participants who received plerixafor, underwent transplantation, and were evaluable 12 months post transplant. The one participant who did not have a durable graft at 12 months had received chemotherapy for relapse approximately 9 months after transplantation.","reportingStatus":"POSTED","timeFrame":"Approximately 13 months (12 months post-transplant )","title":"Number of Participants With Durable Engraftment 12 Months After Transplantation","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"participants"}